This week I present to you: Olgram, Augmedics, Outpace Bio
3.8 million for anti-heart attack startup Vantis
April 1, 2021: The Munich health startup Vantis has received seed funding of 3.8 million euros. Btov, Firstminute Capital and several business angels have invested. Vantis is developing a digital therapy solution for cardiovascular patients to prevent heart attacks, among other things. This should come on the market in the second half of 2021.
Wunder wird zum Mobility-Finanzierer | GS Startup-Ticker - Business Insider
Alles, was man über Startups wissen muss. Auf einen Blick. Die Kurznachrichten aus der Szene könnt ihr hier verfolgen.
Eliem Therapeutics Launches with $80M in Financing
Eliem Therapeutics, Inc., a Redmond, WA and Cambridge, England-based company delivering therapies that allow patients to live on their own terms, launched with $80m in financing since its inception in 2019.
Backers included RA Capital Management, Access Biotechnology, and Intermediate Capital Group (ICG).
Led by President and Chief Executive Officer Bob Azelby, Eliem aims to develop and commercialize therapies treating neuronal excitability disorders such as chronic pain, depression, epilepsy, and anxiety – conditions that cause deep suffering for tens of millions of people each day.
Eliem Therapeutics Launches with $80M in Financing | FinSMEs
Eliem Therapeutics, Inc., a Redmond, WA and Cambridge, England-based company delivering therapies that allow patients to live on their own terms, launched with $80m in financing since its inception in 2019
Olgram Raises €1.5M in Seed Funding
Olgram, a Brehan, France-based biotechnology company developing marine molecules for the prevention and control of bacterial infections, raised €1.5m in seed funding.
The backers were not disclosed.
Founded in 2019 and led by Pierre Rocheteau, CEO, Olgram is a biotechnology company developing marine molecules for the prevention and control of chronic bacterial infections. The company has 2 product candidates targeting infections. Olgram will first focus its efforts on cystic fibrosis, an orphan disease in which 35% of patients suffer from chronic Pseudomonas aeruginosa infections in adulthood (a pathogenic bacterium) leading to their premature death. In a second phase, the company will target nosocomial infections in immunocompromised patients after head trauma.
The company intends to use the funds to accelerate the development of anti-infectious molecules capable of eliminating the bacteria responsible for chronic relapses. To do so, Olgram is characterizing, modifying and optimizing peptides and a marine molecule, MSP (Marine Sulfated Polysaccharide).
Olgram Raises €1.5M in Seed Funding | FinSMEs
Olgram, a Brehan, France-based biotechnology company developing marine molecules for the prevention and control of bacterial infections, raised €1.5m in seed funding
Entrada Therapeutics Closes $116M Series B Financing
Entrada Therapeutics Inc., a Boston, MA-based biotechnology company dedicated to advancing treatment of devastating diseases using intracellular biologics, closed a $116m Series B financing.
The round was led by Wellington Management Company.
Led by Dipal Doshi, President and Chief Executive Officer, Entrada Therapeutics leverages its proprietary Endosomal Escape Vehicle (EEV)TM platform to create a diverse pipeline of oligonucleotide, antibody, enzyme, protein and peptide programs to target and engage underlying drivers of diseases.
The company plans to use the funds to advance its diverse pipeline to the clinic. Included in this pipeline are several of Entrada’s oligonucleotide programs for the treatment of multiple neuromuscular diseases, led by Duchenne muscular dystrophy (DMD). In addition, the company is applying its proprietary Endosomal Escape Vehicle (EEV)TM platform to expand beyond neuromuscular diseases into additional therapeutic areas.
Entrada Therapeutics Closes $116M Series B Financing | FinSMEs
Entrada Therapeutics Inc., a Boston, MA-based biotechnology company dedicated to advancing treatment of devastating diseases using intracellular biologics, closed a $116m Series B financing
Metrion Biosciences Raises £2.75M in Funding
Metrion Biosciences, a Cambridge, UK-based contract research organisation (CRO) catering to the drug discovery market, raised £2.75m in funding.
Gresham House Ventures made a £2.25m investment. Gresham House Ventures’ investment is led by Maya Ward, associate director, supported by investment directors Brendan Gulston and Tom Makey. Maya will join Metrion’s Board as a non-executive director.
Led by Keith McCullagh, chairman, Metrion Biosciences is a specialist contract research company providing drug discovery services to the worldwide pharmaceutical and biotechnology industry. The company is a leader in the field of ion channel biology and works with life science companies to assess the activity of innovative new compounds on human ion channels associated with disease, as well as to screen potential new drugs for off-target effects.
The company intends to use the funds to increase its capacity through enlarged laboratory facilities and specialist equipment, adding regulated cardiac safety testing services and growing its engineered cell line library, as well as to expand its presence in the US.
Metrion Biosciences Raises £2.75M in Funding | FinSMEs
Metrion Biosciences, a Cambridge, UK-based contract research organisation (CRO) catering to the drug discovery market, raised £2.75m in funding
Augmedics Raises $36M in Series C Funding
Augmedics, a Chicago, IL-based provider of an augmented reality surgical image guidance solutions, raised $36m in Series C financing.
H.I.G. Capital, Revival Healthcare Capital, and Almeda Ventures led this financing round, joined by two strategic investors including HCA Healthcare Health Insight Capital, as well as existing investor XR Invest (formally known as AO Invest).
Led by Nissan Elimelech, CEO and founder, Augmedics is an augmented reality surgical image guidance company that aims to improve healthcare by augmenting surgery. Its FDA-cleared xvision Spine System is an augmented reality guidance system for surgery, which allows surgeons to “see” the patient’s anatomy through skin and tissue as if they have “x-ray vision,” and to accurately navigate instruments and implants during spine procedures. The system has now launched and is being used in renowned hospitals and surgical centers in the U.S. Augmedics plans to explore additional surgical applications for xvision beyond spinal surgery.
The company intends to use the funds to continue its commercialization throughout the U.S. and into OUS markets, develop the next generation of products, expand to new indications, and obtain CE certification for sales in Europe.
Augmedics Raises $36M in Series C Funding | FinSMEs
Augmedics, a Chicago, IL-based provider of an augmented reality surgical image guidance solutions, raised $36m in Series C financing
Outpace Bio Raises $30M in Series A Funding
Outpace Bio, a Seattle, WA-based biotechnology company building a platform to create next-generation smart cell therapies, closed a $30m Series A financing round.
The round was led by Artis Ventures and Lyell Immunopharma, Inc., with participation from Abstract Ventures, Civilization Ventures, Mubadala Capital (the asset management arm of Mubadala Investment Company), Playground Global, Sahsen Ventures, and WRF Capital.
Founded by Lyell co-founders Marc Lajoie and Scott Boyken, along with a scientific team that spun out of Lyell Immunopharma, Outpace Bio is creating smart cell therapies using protein design and synthetic biology. The company collaborates with industry leaders, incorporating their biological insights and clinical expertise to create mechanism-driven solutions to improve the safety and efficacy of cell and gene therapies. Its platform combines the design of improved biological functions with cellular control modalities, harnessing the full complexity of cellular biology to tackle incurable disease.
The company intends to use the funds to demonstrate proof of principle for its platform.
Outpace Bio Raises $30M in Series A Funding | FinSMEs
Outpace Bio, a Seattle, WA-based biotechnology company building a platform to create next-generation smart cell therapies, closed a $30m Series A financing round
CirrusMD Raises $20M in Series C Funding
CirrusMD, a Denver, CO-based provider of on-demand virtual care services, raised $20m in Series C funding.
The round was led by Blue Venture Fund, with participation from 7wireVentures, Drive Capital and the Colorado Impact Fund, bringing total funding to $46m.
The company intends to use the funds to continue to expand solution capabilities, enhance user and provider experiences, increase scalability, and drive innovation to support employer and health plan customers.
Led by Andrew Altorfer, CEO, CirrusMD is a telemedicine company that allows patients to quickly reach a live, licensed physician via text-based (or web) app, then conduct a care encounter at their pace and convenience. Available 24/7/365, CirrusMD’s integrated care is delivered via multi-specialty, board-certified doctors who can treat a broad range of conditions, from acute to chronic, and from primary care to specialty areas, including behavioral health. It is available to nearly 10 million users across all 50 states, and exclusively offered through employers and health plans.
CirrusMD Raises $20M in Series C Funding | FinSMEs
CirrusMD, a Denver, CO-based provider of on-demand virtual care services, raised $20m in Series C funding
Nuclein Raises $14M in Series B Funding
Nuclein, LLC, an Austin, Texas-based medical device company, closed a $14m Series B funding round.
The round was led by Trinity Private Equity Group, a Southlake, Texas-based private equity firm.
The company intends to use the funds to to commercialize its novel, hand-held PCR platform designed as a disposable, all-in-one, self-test for infectious disease diagnosis.
Led by Alan Blake, CEO and co-founder, and Dr. Richard Crockett, president and co-founder, Nuclein provides a device that runs real-time PCR, does not require technical expertise to operate, and delivers battery-powered, sample-to-answer results from saliva in under one hour, without the need to mail in a sample. While the Nuclein technology platform has been designed to detect any infectious disease target, the company is currently focusing on COVID-19 to assist with the ongoing pandemic.
Nuclein Raises $14M in Series B Funding | FinSMEs
Nuclein, LLC, an Austin, Texas-based medical device company, closed a $14m Series B funding round
New Equilibrium Biosciences Raises $10M in Seed Funding
New Equilibrium Biosciences, a Cambridge, Mass.-based company that advances a rational drug design against intrinsically disordered proteins (IDPs), closed a $10m in seed funding.
RA Capital Management made the investment. New Equilibrium previously closed $350k in grants from the National Science Foundation and Massachusetts Life Sciences Center, as well as a $250k pre-seed from the Petri Life Sciences Incubator in Boston. Petri committed an additional $500,000 to the $10m seed.
The company intends to use the funds to scale up R&D facility, expand the team, and accelerate programs targeting IDPs while exploring strategic partnerships.
Led by Dr. Virginia Burger, Founder and CEO, New Equilibrium provides a platform that reveals opportunities for structure-based design by learning biophysics with AI. NEQ’s platform combines AI and biophysics to reveal experimentally-invisible conformations of shapeshifting proteins. This technology enables the rational design of drugs targeting the elusive class of intrinsically disordered proteins, including many of the most desirable targets for cancer, neurodegeneration, and other indications.
New Equilibrium Biosciences Raises $10M in Seed Funding
New Equilibrium Biosciences, a Cambridge, Mass.-based company that advances a rational drug design against intrinsically disordered proteins (IDPs), closed a $10m in seed funding
Bioheng Biotech Raises $80M in Series B Financing
Bioheng Biotech Co., Ltd., a Nanjing, China-based clinical-stage biotechnology company dedicated on developing novel cellular immunotherapy for cancer, raised $80m in Series B financing.
The round was co-led by GL Ventures, the venture capital unit of Hillhouse Capital, Decheng Capital and Octagon Capital, with participation from BlueRun Ventures China and Shenzhen Capital Group Company.
The company intends to use the funds to advance R&D capabilities, process development and clinical trials.
Led by Dr. Xiaohong He, Founder and Chief Executive Officer, Bioheng is a clinical-stage biotech company focusing on the development and commercialization of novel allogeneic cellular immunotherapy for immediate treatment to cancer patients, which may increase the affordability and accessibility through overcoming obstacles encountered by autologous cell therapy.
Bioheng Biotech Raises $80M in Series B Financing | FinSMEs
Bioheng Biotech Co., Ltd., a Nanjing, China-based clinical-stage biotechnology company dedicated on developing novel cellular immunotherapy for cancer, raised $80m in Series B financing
Bank of America Announces Acquisition of Healthcare Payment & Tech Company Axia Technologies
Bank of America announced on Friday it has acquired Axia Technologies, Inc. (AxiaMed), a healthcare payment and technology company that is focused on facilitating secure patient payments.
Founded in 2015, AxiaMed reportedly provides a gateway and terminal software solution, powering many healthcare providers to offer end-to-end, omni-channel patient payment solutions. Its integrated offerings help the financial performance of healthcare providers by expanding the payment options available to patients and streamlining administrative workflows.
Bank of America Announces Acquisition of Healthcare Payment & Tech Company Axia Technologies
Bank of America announced on Friday it has acquired Axia Technologies, Inc. (AxiaMed), a healthcare payment and technology company that is focused on facilitating secure patient payments. The banking giant reported that the acquisition will deepen and expand its payment offerings for healthcare clients, as
Cloudmed Buys Databound
Cloudmed, an Atlanta, GA-based provider of revenue intelligence solutions for healthcare providers, acquired Databound, an Ithaca, NY-based healthcare technology company specializing in Robotic Process Automation.
The amount of the deal was not disclosed.
Together, Cloudmed and Databound will deliver accuracy, productivity, and revenue opportunities through automation technology and human expertise.
Led by Paul Martin, President and CEO, Databound provides specialized automation software and services designed for the healthcare revenue cycle, which help organizations increase productivity, save time, and capture missed revenue.
Led by Lee Rivas, Chief Executive Officer, Cloudmed is a healthcare technology company focused on Revenue Intelligence™ and data-driven insights. Its platform utilizes intelligent automation and human expertise to allow providers enhance productivity and increase revenue. The company partners with over 3,100 healthcare providers in the United States and recovers over $1.5 billion of underpaid or unidentified revenue for its clients annually.
